RS64815B1 - Lečenje ćelija kancera koje prekomerno eksprimiraju receptore za somatostatin primenom derivata oktreotida heliranih sa radioizotopima - Google Patents

Lečenje ćelija kancera koje prekomerno eksprimiraju receptore za somatostatin primenom derivata oktreotida heliranih sa radioizotopima

Info

Publication number
RS64815B1
RS64815B1 RS20231056A RSP20231056A RS64815B1 RS 64815 B1 RS64815 B1 RS 64815B1 RS 20231056 A RS20231056 A RS 20231056A RS P20231056 A RSP20231056 A RS P20231056A RS 64815 B1 RS64815 B1 RS 64815B1
Authority
RS
Serbia
Prior art keywords
ocreotide
chelated
radioisotopes
derivatives
treatment
Prior art date
Application number
RS20231056A
Other languages
English (en)
Inventor
Amal Saidi
Izabela Tworowska
Nilesh Wagh
Ebrahim S Delpassand
Federico Rojas-Quijano
Paul Jurek
Garry E Kiefer
Tania A Stallons
Julien Torgue
Original Assignee
Radiomedix Inc
Orano Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radiomedix Inc, Orano Med filed Critical Radiomedix Inc
Publication of RS64815B1 publication Critical patent/RS64815B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RS20231056A 2017-01-12 2018-01-12 Lečenje ćelija kancera koje prekomerno eksprimiraju receptore za somatostatin primenom derivata oktreotida heliranih sa radioizotopima RS64815B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762445541P 2017-01-12 2017-01-12
EP18703122.4A EP3568205B1 (en) 2017-01-12 2018-01-12 Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
PCT/US2018/013640 WO2018132751A1 (en) 2017-01-12 2018-01-12 Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes

Publications (1)

Publication Number Publication Date
RS64815B1 true RS64815B1 (sr) 2023-12-29

Family

ID=61157311

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20231056A RS64815B1 (sr) 2017-01-12 2018-01-12 Lečenje ćelija kancera koje prekomerno eksprimiraju receptore za somatostatin primenom derivata oktreotida heliranih sa radioizotopima

Country Status (19)

Country Link
US (1) US11541133B2 (sr)
EP (1) EP3568205B1 (sr)
JP (1) JP7084417B2 (sr)
KR (1) KR102296752B1 (sr)
CN (1) CN110678227B (sr)
AU (1) AU2018207190B2 (sr)
CA (1) CA3050094C (sr)
DK (1) DK3568205T3 (sr)
ES (1) ES2960030T3 (sr)
FI (1) FI3568205T3 (sr)
HR (1) HRP20231458T1 (sr)
HU (1) HUE063981T2 (sr)
IL (1) IL268012B (sr)
LT (1) LT3568205T (sr)
PL (1) PL3568205T3 (sr)
PT (1) PT3568205T (sr)
RS (1) RS64815B1 (sr)
SI (1) SI3568205T1 (sr)
WO (1) WO2018132751A1 (sr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3784294A4 (en) * 2018-04-27 2022-01-05 University of Iowa Research Foundation COMPOSITIONS FOR CHELATING METALS AT LOW TEMPERATURES
KR20220132556A (ko) * 2020-01-29 2022-09-30 유니버시티 오브 아이오와 리써치 파운데이션 암에 대한 펩티드 수용체 표적화 방사성핵종 치료의 테라노스틱 성능을 개선하기 위한 구조 최적화 방법
US20230382819A1 (en) * 2020-10-14 2023-11-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Processes for synthesis of alpha-emitting radiopharmaceuticals
NL2028075B1 (en) * 2021-04-26 2022-11-03 Alphathera Ag Targeting system for cancer comprising a radioisotope
CN113277989B (zh) * 2021-04-27 2022-05-31 中南大学湘雅医院 一种68Ga标记的分子探针、制备方法及其应用
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
EP4282439A1 (en) 2022-05-23 2023-11-29 Erasmus University Rotterdam Medical Center Radioisotope labeled sstr2-agonists with linkers
WO2024101993A1 (en) 2022-11-09 2024-05-16 Coretag IP B.V. Targeting system for cancer treatment

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004017D0 (en) 1990-02-22 1990-04-18 Krenning Eric P Improvements in or relating to organic compounds
US6017512A (en) * 1992-06-23 2000-01-25 Diatide, Inc. Radiolabeled peptides
GB9417873D0 (en) 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
US5830431A (en) 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
MY147327A (en) 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides
US7361346B1 (en) 1996-05-15 2008-04-22 Altarex Corp. Therapeutic compositions that produce an immune response
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
US6866837B2 (en) 1998-06-05 2005-03-15 Mallinckrodt Inc. Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors
US6926883B1 (en) 1999-06-29 2005-08-09 Mallinckrodt Inc Group (VII) transition-metal complexes with multidentate aminopolycarboxylate ligands and a kit for producing them
US6358491B1 (en) 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
NZ522200A (en) 2000-04-26 2004-07-30 Biosynthema Inc RGD (ARG-GLY-ASP) coupled to (neuro)peptides
AU1123202A (en) 2000-09-15 2002-03-26 Sloan Kettering Inst Cancer Targeted alpha particle therapy using actinium-225 conjugates
DE60231801D1 (de) 2001-04-23 2009-05-14 Mallinckrodt Inc Tc und re markierte radioaktive glycosylierte octreotid-derivate
EP1283216A1 (en) 2001-08-10 2003-02-12 Mallinckrodt Inc. Somatostatin analogues binding to all somatostatin receptor subtypes and their use
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7122622B2 (en) * 2002-04-16 2006-10-17 Biosynthema Inc. Peptide compounds having improved binding affinity to somatostatin receptors
EP1793868B1 (en) * 2004-09-23 2010-12-29 Guerbet Liposomal contrast agents for cest imaging
US20070025910A1 (en) * 2005-07-29 2007-02-01 Norenberg Jeffrey P Anticancer therapy
US8097237B2 (en) 2005-08-23 2012-01-17 Stc.Unm Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
EP1988925A2 (en) 2006-02-24 2008-11-12 Mallinckrodt, Inc. Bifunctional resorcinol, thioresorcinol, and dithioresorcinol derivative metal chelating conjugates
ES2397116T3 (es) 2006-03-14 2013-03-04 Mallinckrodt, Inc. Complejos de metal de derivados de tretraazamacrociclo
US20160045626A1 (en) * 2007-01-11 2016-02-18 Immunomedics, Inc. Methods and Compositions for Improved Labeling of Targeting Peptides
BRPI0809442A2 (pt) 2007-03-27 2014-09-09 Radiomedix Inc Composições para terapia e formação de imagens direcionada
US20100316566A1 (en) 2008-02-27 2010-12-16 Radiomedix Inc. Radiolabeled hedgehog derivatives for imaging and therapy
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
US8623322B2 (en) 2008-06-13 2014-01-07 Stc.Unm Non-invasive diagnostic agents and methods of diagnosing infectious disease
ES2743412T3 (es) 2008-09-30 2020-02-19 Curium Us Llc Productos conjugados de hexosa y compuestos de coordinación de metales para la generación de imágenes
US9603954B2 (en) 2009-07-22 2017-03-28 Actinium Pharmaceuticals Inc. Methods for generating radioimmunoconjugates
US8986651B2 (en) 2009-11-30 2015-03-24 Stc.Unm Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
WO2012027556A1 (en) 2010-08-25 2012-03-01 William Marsh Rice University Nanostructures comprising radioisotopes and/or metals
US9180214B1 (en) 2011-04-22 2015-11-10 Stc.Unm Gonadotropin-releasing hormone receptor-targeting peptides and their use to treat and diagnose cancer
US9550001B2 (en) 2011-06-20 2017-01-24 Radiomedix Inc. Compositions, methods of synthesis and use of carbohydrate targeted agents
ES2842998T3 (es) * 2011-08-31 2021-07-15 Somscan Aps Trazador TEP para imágenes de tumores neuroendocrinos
JP2015501654A (ja) * 2011-12-13 2015-01-19 ノルディック ナノベクター アーエス 治療用キメラ型抗cd37抗体hh1
EP3536347A1 (en) 2012-09-25 2019-09-11 Advanced Accelerator Applications USA, Inc. Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer
EP2920156B9 (en) 2012-10-02 2017-04-19 Guerbet Process for the preparation of macrocyclic polyazacarboxylate ligands and chelates
US20140147381A1 (en) * 2012-11-29 2014-05-29 Gregory David Espenan 89zr compounds, to include somatostatin, apparatus and products comprising such compounds, methods of making same, and methods of using same for radio imaging and/or treatment
EP3011339A4 (en) 2013-06-18 2017-01-25 Aminomedix Inc. Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids
US20150157742A1 (en) 2013-12-11 2015-06-11 The European Atomic Energy Community (Euratom), Represented By The European Commission SYNTHESIS OF BIOLOGICAL COMPOUNDS LABELED WITH THE ALPHA EMITTER Ac-225
GB201417067D0 (en) * 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
WO2016138448A1 (en) * 2015-02-27 2016-09-01 Schmitthenner Hans F Transmetalation methods for the synthesis of pet and spect imaging agents
EP3294316A4 (en) * 2015-05-06 2018-10-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Radiotherapeutic and companion imaging agents to target mc1r
EP3111959B1 (en) * 2015-07-03 2017-09-13 Oncoinvent AS Radiotherapeutic particles and suspensions
CN106084005B (zh) * 2016-06-15 2020-02-14 广州军区广州总医院 靶向生长抑素受体的Al18F-NOTA-PEG6-TATE及其制备方法和应用
FR3069245B1 (fr) * 2017-07-21 2019-07-26 Guerbet Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales
KR20220132556A (ko) * 2020-01-29 2022-09-30 유니버시티 오브 아이오와 리써치 파운데이션 암에 대한 펩티드 수용체 표적화 방사성핵종 치료의 테라노스틱 성능을 개선하기 위한 구조 최적화 방법

Also Published As

Publication number Publication date
PL3568205T3 (pl) 2024-03-18
FI3568205T3 (fi) 2023-11-01
US20190336623A1 (en) 2019-11-07
LT3568205T (lt) 2024-02-12
IL268012B (en) 2021-12-01
SI3568205T1 (sl) 2023-12-29
CN110678227A (zh) 2020-01-10
CA3050094C (en) 2024-01-02
AU2018207190A1 (en) 2019-08-29
CN110678227B (zh) 2023-03-21
CA3050094A1 (en) 2018-07-19
KR102296752B1 (ko) 2021-09-02
JP2020505445A (ja) 2020-02-20
PT3568205T (pt) 2023-10-26
WO2018132751A1 (en) 2018-07-19
AU2018207190B2 (en) 2020-12-03
DK3568205T3 (da) 2023-10-09
HRP20231458T1 (hr) 2024-05-10
JP7084417B2 (ja) 2022-06-14
IL268012A (en) 2019-09-26
HUE063981T2 (hu) 2024-02-28
KR20200016196A (ko) 2020-02-14
EP3568205B1 (en) 2023-08-16
ES2960030T3 (es) 2024-02-29
US11541133B2 (en) 2023-01-03
EP3568205A1 (en) 2019-11-20

Similar Documents

Publication Publication Date Title
HUE063981T2 (hu) Szomatosztatin receptorokat túlexpresszáló rákos sejtek kezelése radioizotópokkal kelátképzett oktreotid-származékok alkalmazásával
IL283733A (en) Methods for treating cancer using activated t cells
HK1247202A1 (zh) 用於治療癌症的化合物
IL282655A (en) Methods of treating developmental disorders using pipradrol
IL263678B (en) Compounds for use in the treatment of breast cancer +ar
HK1223557A1 (zh) 用於治療局部晚期或轉移性雌激素受體陽性乳腺癌的雌激素受體調節劑
PT3063173T (pt) Anticorpos anti-cd38 específicos para o tratamento de cancros humanos
SI3473263T1 (sl) Kombinirani pripravki za zdravljenje raka
EP3386522A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF HER2-POSITIVE METASTATIC BREAST CANCER
IL247436A0 (en) Preparations and methods for treating tumors that overexpress her2/neu
SG11201701051RA (en) A method for prognosis of ovarian cancer, patient's stratification
IL282701A (en) Methods for the synthesis of a radionuclide complex
HK1251009B (zh) 用於治療癌症的治療組合物
HK1253082A1 (zh) 診斷乳腺癌的方法
IL277235A (en) Preparations containing octreotide for the treatment of acromegaly
IL266917A (en) Methods for treating prolactin receptor-positive breast cancer
IL258671A (en) A therapeutic agent for breast cancer
ZA201802831B (en) Composition for the treatment of igf-1r expressing cancer
PT3296294T (pt) Composto para tratamento ou prevenção do cancro de mama
LT2809327T (lt) Hidroksialkilo krakmolas, skirtas vėžio gydymui, sumažinant naviko augimo greičius
IL246540A0 (en) Freezeald receptor antibodies for cancer treatment
IL259781A (en) Uses of pyrimido-pyridazinones to treat cancer
EP3121274A4 (en) METHOD FOR PREDICTING RESPONSIVENESS TO CANCER TREATMENT USING p300-INHIBITING COMPOUND
EP3387443A4 (en) INTEGRATED ANALYSIS TO DETERMINE PROGNOSIS AFTER THE TREATMENT OF PRIMARY BREAST CANCER
IL255167A0 (en) Compounds for the treatment of cancer